<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1130-0108</journal-id>
<journal-title><![CDATA[Revista Española de Enfermedades Digestivas]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. esp. enferm. dig.]]></abbrev-journal-title>
<issn>1130-0108</issn>
<publisher>
<publisher-name><![CDATA[Sociedad Española de Patología Digestiva]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1130-01082018001000006</article-id>
<article-id pub-id-type="doi">10.17235/reed.2018.5602/2018</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Role of the PNPLA3 polymorphism rs738409 on silymarin + vitamin E response in subjects with non-alcoholic fatty liver disease]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Aller]]></surname>
<given-names><![CDATA[Rocío]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
<xref ref-type="aff" rid="A a"/>
<xref ref-type="aff" rid="A5"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Laserna]]></surname>
<given-names><![CDATA[Cristina]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rojo]]></surname>
<given-names><![CDATA[Miguel-Ángel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Mora]]></surname>
<given-names><![CDATA[Natalia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[García]]></surname>
<given-names><![CDATA[Concepción]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Pina]]></surname>
<given-names><![CDATA[María]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Sigüenza]]></surname>
<given-names><![CDATA[Rebeca]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Durà]]></surname>
<given-names><![CDATA[Miguel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Primo]]></surname>
<given-names><![CDATA[David]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Izaola]]></surname>
<given-names><![CDATA[Olatz]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[De-Luis]]></surname>
<given-names><![CDATA[Daniel-A.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Clínico Universitario Departments of Gastroenterology ]]></institution>
<addr-line><![CDATA[Valladolid ]]></addr-line>
<country>Spain</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Hospital Clínico Universitario Family and Community Medicine ]]></institution>
<addr-line><![CDATA[Valladolid ]]></addr-line>
<country>Spain</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Universidad de Valladolid Medicine School ]]></institution>
<addr-line><![CDATA[Valladolid ]]></addr-line>
<country>Spain</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Hospital Clínico Universitario Departments of Radiology ]]></institution>
<addr-line><![CDATA[Valladolid ]]></addr-line>
<country>Spain</country>
</aff>
<aff id="Af5">
<institution><![CDATA[,Universidad de Valladolid Hospital Clínico Universitario Center of Investigation of Endocrinology and Nutrition. Department of Endocrinology and Nutrition Medicine School]]></institution>
<addr-line><![CDATA[Valladolid ]]></addr-line>
<country>Spain</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>10</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>10</month>
<year>2018</year>
</pub-date>
<volume>110</volume>
<numero>10</numero>
<fpage>634</fpage>
<lpage>640</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_arttext&amp;pid=S1130-01082018001000006&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_abstract&amp;pid=S1130-01082018001000006&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_pdf&amp;pid=S1130-01082018001000006&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Background:  non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in developed countries. Lifestyle changes are the pillar of the treatment, although a pharmacological approach is sometimes required in the case of a failure to respond/adhere to the diet.  Objective:  the aim of this study was to evaluate the effect of silymarin and the influence of the patatin-like phospholipase domain-containing protein 3 (PNPLA3) variant on the response to treatment in patients with NAFLD in a pilot study.  Methods:  a total of 54 patients with a NAFLD proven biopsy were enrolled in an open prospective study and were treated with Eurosil 85(r) (silymarin + vitamin E) for six months. Biochemical parameters and cardiovascular risk factors (diabetes mellitus, dyslipidemia, hypertriglyceridemia, arterial hypertension and HOMA-IR &gt; 2.5) were recorded before and after six months of treatment. Non-invasive indexes (fatty liver index, lipid accumulation product and NAFLD-fibrosis score) were also calculated. The rs738409 PNPLA3 gene polymorphism status was also determined.  Results:  significant statistical changes from baseline values after six months of treatment were observed in transaminases levels but not in non-invasive index markers. Twenty patients (37.1%) were G allele carriers and had a higher percentage of lobular inflammation and ballooning on the basal liver biopsy. Patients with the G allele had a smaller decrease in transaminases levels after treatment with silymarin + vitamin E than non-G-allele carriers.  Conclusions:  treatment with silymarin + vitamin E produced a decrease in transaminases after six months of treatment without an accompanying weight loss. PNPLA3 G-allele carriers responded poorly to the treatment.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Non-alcoholic fatty liver disease]]></kwd>
<kwd lng="en"><![CDATA[Silymarin]]></kwd>
<kwd lng="en"><![CDATA[Liver biopsy]]></kwd>
<kwd lng="en"><![CDATA[PNPLA3]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Epidemiology of a fast emerging disease in the Asia-Pacific region non-alcoholic fatty liver disease]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wah-Kheong]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Khean-Lee]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<source><![CDATA[Hepatol Int]]></source>
<year>2013</year>
<volume>7</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>65-71</page-range></nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The epidemiology of non-alcoholic fatty liver disease]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bellentani]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<source><![CDATA[Liver Int]]></source>
<year>2017</year>
<volume>37</volume>
<numero>Suppl 1</numero>
<issue>Suppl 1</issue>
<page-range>81-4</page-range></nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Nonalcoholic fatty liver disease as a nexus of metabolic and hepatic diseases]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Samuel]]></surname>
<given-names><![CDATA[VT]]></given-names>
</name>
<name>
<surname><![CDATA[Shulman]]></surname>
<given-names><![CDATA[GI]]></given-names>
</name>
</person-group>
<source><![CDATA[Cell Metabolism]]></source>
<year>2018</year>
<volume>27</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>22-41</page-range></nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vilar-Gómez]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez-Pérez]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Calzadilla-Bertot]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<source><![CDATA[Gastroenterology]]></source>
<year>2015</year>
<volume>149</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>367-78.e5</page-range></nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Promrat]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Kleiner]]></surname>
<given-names><![CDATA[DE]]></given-names>
</name>
<name>
<surname><![CDATA[Niemeier]]></surname>
<given-names><![CDATA[HM]]></given-names>
</name>
</person-group>
<source><![CDATA[Hepatology]]></source>
<year>2010</year>
<volume>51</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>121-9</page-range></nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Development and validation of a noninvasive prediction model for nonalcoholic steatohepatitis resolution after lifestyle intervention]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vilar-Gómez]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Yasells-García]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez-Pérez]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<source><![CDATA[Hepatology]]></source>
<year>2016</year>
<volume>63</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1875-87</page-range></nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[PNPLA3 polymorphism increases risk for and severity of chronic hepatitis C liver disease]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Salameh]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Masadeh]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Al Hanayneh]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[World J Hepatol]]></source>
<year>2016</year>
<volume>8</volume>
<numero>35</numero>
<issue>35</issue>
<page-range>1584-92</page-range></nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Romeo]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Kozlitina]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Xing]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<source><![CDATA[Nat Genet]]></source>
<year>2008</year>
<volume>40</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1461-5</page-range></nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[PNPLA3 I148M variant in nonalcoholic fatty liver disease demographic and ethnic characteristics and the role of the variant in nonalcoholic fatty liver fibrosis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[LZ]]></given-names>
</name>
<name>
<surname><![CDATA[Xin]]></surname>
<given-names><![CDATA[YN]]></given-names>
</name>
<name>
<surname><![CDATA[Geng]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<source><![CDATA[World J Gastroenterol]]></source>
<year>2015</year>
<volume>21</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>794-802</page-range></nlm-citation>
</ref>
<ref id="B10">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[PNPLA3 I148M variant and hepatocellular carcinoma a common genetic variant for a rare disease]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Valenti]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Dongiovanni]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Ginanni Corradini]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<source><![CDATA[Dig Liver Dis]]></source>
<year>2013</year>
<volume>45</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>619-24</page-range></nlm-citation>
</ref>
<ref id="B11">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Pathology of non-alcoholic fatty liver disease]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bedossa]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<source><![CDATA[Liver Int]]></source>
<year>2017</year>
<volume>37</volume>
<numero>Suppl 1</numero>
<issue>Suppl 1</issue>
<page-range>85-9</page-range></nlm-citation>
</ref>
<ref id="B12">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The fatty liver index a simple and accurate predictor of hepatic steatosis in the general population]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bedogni]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Bellentani]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Miglioli]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<source><![CDATA[BMC Gastroenterol]]></source>
<year>2006</year>
<volume>6</volume>
<page-range>33</page-range></nlm-citation>
</ref>
<ref id="B13">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Friedewald]]></surname>
<given-names><![CDATA[WT]]></given-names>
</name>
<name>
<surname><![CDATA[Levy]]></surname>
<given-names><![CDATA[RI]]></given-names>
</name>
<name>
<surname><![CDATA[Fredrickson]]></surname>
<given-names><![CDATA[DS]]></given-names>
</name>
</person-group>
<source><![CDATA[Clin Chem]]></source>
<year>1972</year>
<volume>18</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>499-502</page-range></nlm-citation>
</ref>
<ref id="B14">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[A simple index of lipid overaccumulation is a good marker of liver steatosis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bedogni]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Kahn]]></surname>
<given-names><![CDATA[HS]]></given-names>
</name>
<name>
<surname><![CDATA[Bellentani]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<source><![CDATA[BMC Gastroenterol]]></source>
<year>2010</year>
<volume>10</volume>
<page-range>98</page-range></nlm-citation>
</ref>
<ref id="B15">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The NAFLD fibrosis score a noninvasive system that identifies liver fibrosis in patients with NAFLD]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Angulo]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Hui]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Marchesini]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<source><![CDATA[Hepatology]]></source>
<year>2007</year>
<volume>45</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>846-54</page-range></nlm-citation>
</ref>
<ref id="B16">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Improvement in liver histology due to lifestyle modification is independently associated with improved kidney function in patients with non-alcoholic steatohepatitis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vilar-Gómez]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Calzadilla-Bertot]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Friedman]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
</person-group>
<source><![CDATA[Aliment Pharmacol Ther]]></source>
<year>2017</year>
<volume>45</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>332-44</page-range></nlm-citation>
</ref>
<ref id="B17">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Efficacy of dietary and physical activity intervention in non-alcoholic fatty liver disease a systematic review]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kenneally]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Sier]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
<name>
<surname><![CDATA[Moore]]></surname>
<given-names><![CDATA[JB]]></given-names>
</name>
</person-group>
<source><![CDATA[BMJ Open Gastroenterol]]></source>
<year>2017</year>
<volume>4</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>e000139</page-range></nlm-citation>
</ref>
<ref id="B18">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Stage of change and motivation to healthier lifestyle in non-alcoholic fatty liver disease]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Centis]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Moscatiello]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Bugianesi]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<source><![CDATA[J Hepatol]]></source>
<year>2013</year>
<volume>58</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>771-7</page-range></nlm-citation>
</ref>
<ref id="B19">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Efficacy of lifestyle changes in subjects with non-alcoholic liver steatosis and metabolic syndrome may be improved with an antioxidant nutraceutical a controlled clinical study]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sorrentino]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Crispino]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Coppola]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<source><![CDATA[Drugs R&amp;D]]></source>
<year>2015</year>
<volume>15</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>21-5</page-range></nlm-citation>
</ref>
<ref id="B20">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Silymarin ascending multiple oral dosing phase I study in noncirrhotic patients with chronic hepatitis C]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hawke]]></surname>
<given-names><![CDATA[RL]]></given-names>
</name>
<name>
<surname><![CDATA[Schrieber]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Soule]]></surname>
<given-names><![CDATA[TA]]></given-names>
</name>
</person-group>
<source><![CDATA[J Clin Pharmacol]]></source>
<year>2010</year>
<volume>50</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>434-49</page-range></nlm-citation>
</ref>
<ref id="B21">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Silybin, a component of sylimarin, exerts anti-inflammatory and anti-fibrogenic effects on human hepatic stellate cells]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Trappoliere]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Caligiuri]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Schmid]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[J Hepatol]]></source>
<year>2009</year>
<volume>50</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1102-11</page-range></nlm-citation>
</ref>
<ref id="B22">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Silymarin suppresses hepatic stellate cell activation in a dietary rat model of non-alcoholic steatohepatitis analysis of isolated hepatic stellate cells]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[SG]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
</person-group>
<source><![CDATA[Int J Mol Med]]></source>
<year>2012</year>
<volume>30</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>473-9</page-range></nlm-citation>
</ref>
<ref id="B23">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[A randomized trial of silymarin for the treatment of nonalcoholic steatohepatitis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chan]]></surname>
<given-names><![CDATA[WK]]></given-names>
</name>
<name>
<surname><![CDATA[Nik-Mustapha]]></surname>
<given-names><![CDATA[NR]]></given-names>
</name>
<name>
<surname><![CDATA[Mahadeva]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<source><![CDATA[Clin Gastroenterol Hepatol]]></source>
<year>2017</year>
<volume>15</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1940-9.e8</page-range></nlm-citation>
</ref>
<ref id="B24">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Silymarin, the antioxidant component and Silybum marianum extracts prevent liver damage]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shaker]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Mahmoud]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Mnaa]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<source><![CDATA[Food Chem Toxicol]]></source>
<year>2010</year>
<volume>48</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>803-6</page-range></nlm-citation>
</ref>
<ref id="B25">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[De Avelar]]></surname>
<given-names><![CDATA[CR]]></given-names>
</name>
<name>
<surname><![CDATA[Pereira]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of silymarin on biochemical indicators in patients with liver disease systematic review with meta-analysis]]></article-title>
<collab>De Farias Costa PR</collab>
<source><![CDATA[World J Gastroenterol]]></source>
<year>2017</year>
<volume>23</volume>
<numero>27</numero>
<issue>27</issue>
<page-range>5004-17</page-range></nlm-citation>
</ref>
<ref id="B26">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Vitamin E in human health and disease]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Clarke]]></surname>
<given-names><![CDATA[MW]]></given-names>
</name>
<name>
<surname><![CDATA[Burnett]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Croft]]></surname>
<given-names><![CDATA[KD]]></given-names>
</name>
</person-group>
<source><![CDATA[Crit Rev Clinical Lab Sci]]></source>
<year>2008</year>
<volume>45</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>417-50</page-range></nlm-citation>
</ref>
<ref id="B27">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Association between vitamin E and non-alcoholic steatohepatitis a meta-analysis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Xu]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Tao]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<source><![CDATA[Int J Clin Exp Med]]></source>
<year>2015</year>
<volume>8</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>3924-34</page-range></nlm-citation>
</ref>
<ref id="B28">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Silibinin modulates lipid homeostasis and inhibits nuclear factor kappa B activation in experimental nonalcoholic steatohepatitis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Salamone]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Galvano]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Cappello]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<source><![CDATA[Transl Res]]></source>
<year>2012</year>
<volume>159</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>477-86</page-range></nlm-citation>
</ref>
<ref id="B29">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Adiponutrin, a transmembrane protein corresponding to a novel dietary- and obesity-linked mRNA specifically expressed in the adipose lineage]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Baulande]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Lasnier]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Lucas]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[J Biol Chem]]></source>
<year>2001</year>
<volume>276</volume>
<numero>36</numero>
<issue>36</issue>
<page-range>33336-44</page-range></nlm-citation>
</ref>
<ref id="B30">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Characterization of the human patatin-like phospholipase family]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wilson]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
<name>
<surname><![CDATA[Gardner]]></surname>
<given-names><![CDATA[SD]]></given-names>
</name>
<name>
<surname><![CDATA[Lambie]]></surname>
<given-names><![CDATA[NM]]></given-names>
</name>
</person-group>
<source><![CDATA[J Lipid Res]]></source>
<year>2006</year>
<volume>47</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1940-9</page-range></nlm-citation>
</ref>
<ref id="B31">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Association of the rs738409 polymorphism in PNPLA3 with liver damage and the development of nonalcoholic fatty liver disease]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hotta]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Yoneda]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Hyogo]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<source><![CDATA[BMC Med Genet]]></source>
<year>2010</year>
<volume>11</volume>
<page-range>172</page-range></nlm-citation>
</ref>
<ref id="B32">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Genetic polymorphisms of the human PNPLA3 gene are strongly associated with severity of non-alcoholic fatty liver disease in Japanese]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kawaguchi]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Sumida]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Umemura]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[PloS One]]></source>
<year>2012</year>
<volume>7</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>e38322</page-range></nlm-citation>
</ref>
<ref id="B33">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Association between patatin-like phospholipase domain containing 3 gene (PNPLA3) polymorphisms and nonalcoholic fatty liver disease a HuGE review and meta-analysis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Xu]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Tao]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<source><![CDATA[Sci Rep]]></source>
<year>2015</year>
<volume>5</volume>
<page-range>9284</page-range></nlm-citation>
</ref>
<ref id="B34">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[PNPLA3 polymorphisms (rs738409) and non-alcoholic fatty liver disease risk and related phenotypes a meta-analysis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[You]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<source><![CDATA[J Gastroenterol Hepatol]]></source>
<year>2015</year>
<volume>30</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>821-9</page-range></nlm-citation>
</ref>
<ref id="B35">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Short-term vitamin E treatment impairs reactive oxygen species signaling required for adipose tissue expansion, resulting in fatty liver and insulin resistance in obese mice]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alcalá]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Calderón-Domínguez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Serra]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<source><![CDATA[PLoS One]]></source>
<year>2017</year>
<volume>12</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>e0186579</page-range></nlm-citation>
</ref>
<ref id="B36">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Significance of genetic polymorphisms in patients with nonalcoholic fatty liver disease]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Miyaaki]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Nakao]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<source><![CDATA[Clin J Gastroenterol]]></source>
<year>2017</year>
<volume>10</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>201-7</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
